immunoglobulin heavy diversity 5-12Genealiases: DK1 · IGHD512
Q-omics provides the consensus-scored IGHD5-12 profile across patient tissues and cancer cell-line models. IGHD5-12 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, IGHD5-12 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, IGHD5-12 RNA expression shows 10,512 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THCA, COAD, and LSCC as cancer lineages where IGHD5-12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHD5-12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHD5-12 survival associations across molecular data types. IGHD5-12 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHD5-12 RNA expression–survival associations across cancer types. High IGHD5-12 expression shows unfavorable associations in THCA, CESC, LIHC and DLBC, but favorable associations in HNSC and BLCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for IGHD5-12 RNA expression.
This table summarizes IGHD5-12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGHD5-12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHD5-12 shows lower tumor expression in COAD and higher tumor expression in LUAD, BRCA and KIRC. The COAD box plot shows higher IGHD5-12 RNA expression in normal versus tumor tissue (log2 FC = −0.420, t-test p = .006).
This table shows molecular features associated with IGHD5-12 in patient tissues and cancer cell lines. In patient samples, IGHD5-12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
